Çö󷺽ºÁ¡¾ÈÇöʾ×(ÃÊ»êÇ÷ç¿À·Î¸ÞÅç·Ð) 10mL FLAREX EYE DROPS SUSPENSION
Àü¹®ÀǾàǰ | »èÁ¦
¼öÀÔÀǾàǰ
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
Èò»ö ³»Áö ȸ¹é»öÀÇ µ¢¾î¸®°¡ ¾ø´Â ±ÕÁúÇÑ Çöʾ×ÀÌ ºÒÅõ¸íÇÑ Èò»ö ÇÃ¶ó½ºÆ½ ¿ë±â¿¡ µç Á¡¾ÈÁ¦
Á¦Á¶È¸»ç
Alcon
ÆÇ¸Åȸ»ç
Çѱ¹¾ËÄÜ(ÁÖ)
Çã°¡Á¤º¸
ÃëÇÏ
(2025.03.26)
BIT ¾àÈ¿ºÐ·ù
¾È°ú¿ë Ç׾˷¯ÁöÁ¦(Eye steroids & antiallergics)
º¹ÁöºÎºÐ·ù
131[¾È°ú¿ëÁ¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
652400692 \0 ¿ø/10mL/º´(2018.03.01) (ÇöÀç¾à°¡) \8,250 ¿ø/10mL/º´(2016.03.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Fluorometholone / S01BA07
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
¸ê±ÕÁ¤Á¦¼ö ,
º¥ÀßÄÚ´½¿°È¹° ,
¼ö»êȳªÆ®·ý ,
¿¡µ¥Æ®»ê³ªÆ®·ý ,
¿°»ê ,
¿°È³ªÆ®·ý ,
ÀλêÁ¦À̼ö¼Ò³ªÆ®·ý ,
Ƽ·Ï»çÆú ,
È÷µå·Ï½Ã¿¡Ä¥¼¿·ê·Î¿À½º
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
652400692
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/10mL/º´(2018.03.01) (ÇöÀç¾à°¡)
\8,250 ¿ø/10mL/º´(2016.03.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
Èò»ö ³»Áö ȸ¹é»öÀÇ µ¢¾î¸®°¡ ¾ø´Â ±ÕÁúÇÑ Çöʾ×ÀÌ ºÒÅõ¸íÇÑ Èò»ö ÇÃ¶ó½ºÆ½ ¿ë±â¿¡ µç Á¡¾ÈÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
1mg/mL¡¿5mL¡¿1EA
ÁÖ¼ººÐÄÚµå
161331COS
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
¾È°Ë ¹× ¾È±¸ÀÇ °á¸·, °¢¸· ¹× ¾È±¸ Àü¹æÀÇ ½ºÅ×·ÎÀÌµå °¨¼ö¼ºÀÇ ¿°Áõ¼º Áúȯ.
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ȸ 1-2¹æ¿ï 1ÀÏ 4ȸ Á¡¾ÈÇÑ´Ù.
óÀ½ 24-48½Ã°£ µ¿¾ÈÀº 2½Ã°£¸¶´Ù 2¹æ¿ï Áõ·® Åõ¿©ÇÒ ¼ö ÀÖ´Ù. Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
±Ý±â
1) ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
2) ´Ü¼ø Æ÷Áø¼º °¢¸·¿°
3) ¿ìµÎ, ¼öµÎ ¹× ±âŸ ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ °¢¸· ¹× °á¸·ÀÇ Áúȯ
4) Áø±Õ¼º Áúȯ
5) ¹ÌÄ¡·áµÈ ±Þ¼º ¼¼±Õ°¨¿°
6) ´«ÀÇ ¹ÌÄÚ¹ÚÅ׸®¾Æ °¨¿° ȯÀÚ
½ÅÁßÅõ¿©
1) ´Ü¼ø Æ÷ÁøÀÇ Ä¡·á¿¡ »ç¿ëÇÒ °æ¿ì¿¡´Â ±ØÈ÷ ÁÖÀÇÇÑ´Ù.
2) Àå±â°£ »ç¿ëÇÏ´Â °æ¿ì ³ì³»Àå, ½Ã½Å°æ ¼Õ»ó, ½Ã·Â ÀúÇÏ ¹× ½Ã¾ßÀÇ °¨Åð ¹× ¹é³»ÀåÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç, ¼÷ÁÖ ¹ÝÀÀ ¾ïÁ¦¿¡ ÀÇÇÑ 2Â÷ ¾È±¸ °¨¿°ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ¼Ò¾Æ¿¡¼ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å À¯¹ß¼º °í¾È¾ÐÁõÀÌ ´õ ½ÉÇÒ ¼ö ÀÖ°í ¼ºÀκ¸´Ù ´õ »¡¸® ¹ß»ýÇÒ ¼ö ÀÖÀ¸¹Ç·Î, ÀÌ´Â ¼Ò¾Æ ȯÀÚ¿¡¼ ƯÈ÷ Áß¿äÇÏ´Ù. À¯¹ß ¼ÒÀÎÀÌ Àִ ȯÀÚ (¿¹: ´ç´¢º´)¿¡¼´Â ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å-À¯¹ß¼º ¾È¾Ð »ó½Â ¹×/¶Ç´Â ¹é³»Àå ¹ß»ýÀÇ À§ÇèÀÌ Áõ°¡ÇÑ´Ù.
3) ±Þ¼º È³ó¼º ¾ÈÁúȯ¿¡ ½ºÅ×·ÎÀ̵带 »ç¿ëÇÒ °æ¿ì °¨¿°ÁõÀ» ÀºÆóÇϰųª ¾ÇÈ ½Ãų ¼ö ÀÖ´Ù.
4) °¢¸· ¶Ç´Â °ø¸·ÀÇ ¹Ú¸·È¸¦ ÃÊ·¡ÇÏ´Â Áúȯ¿¡ ±¹¼Ò¿ë ½ºÅ×·ÎÀ̵带 Àå±â°£ »ç¿ëÇÒ °æ¿ì õ°øÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
ÀÌ»ó¹ÝÀÀ
1) ÀÌ»ó¹ÝÀÀÀÇ ºóµµ´Â ´ÙÀ½ ±âÁØ¿¡ ÀÇÇØ Á¤ÀÇÇÏ¿´´Ù.: ¸Å¿ì ÈçÇÏ°Ô (¡Ã 1/10), ÈçÇÏ°Ô (¡Ã 1/100¿¡¼ <1/10), ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100), µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000) ¹× ¸Å¿ì µå¹°°Ô (<1/10,000) ¶Ç´Â ¾Ë ¼ö ¾øÀ½ (ÀÔ¼öµÈ ÀÚ·á·ÎºÎÅÍ ºóµµ¸¦ ÃßÁ¤ÇÒ ¼ö ¾øÀ½). °¢°¢ÀÇ ºóµµ ±×·ì ³»¿¡¼, ÀÌ»ó¾à¹°¹ÝÀÀÀº Áߴ뼺ÀÌ °¨¼ÒÇÏ´Â ¼øÀ¸·Î ³ªÅ¸³½´Ù. ´ÙÀ½ÀÇ ÀÌ»ó¹ÝÀÀÀº ÀÌ ¾à ¶Ç´Â À¯»çÇÑ ¾È°úÁ¦Á¦ÀÇ »ç¿ëÀ¸·Î º¸°íµÇ¾ú´Ù.
±â°ü
ÀÌ»ó¹ÝÀÀ
¾È°ú°è
ÈçÇÏÁö ¾Ê°Ô: ´« ÀÚ±Ø, ¾È±¸ ÃæÇ÷, ¾È¾Ð»ó½Â
µå¹°°Ô: ´« ºÎÁ¾, ´« °¡·Á¿ò, »êµ¿, ¾È°ËÇϼö, ÇǸ·ÇÏ ¹é³»Àå, ³ì³»Àå
¸Å¿ìµå¹°°Ô: °¢¸· õ°ø
¾Ë ¼ö ¾øÀ½: ½Ã¾ßÈ帲, ´« ÅëÁõ, ´« ºÒÆí°¨, ´«ÀÇ À̹°°¨, ´«¹° Áõ°¡
¸é¿ª°è
µå¹°°Ô: °ú¹Î¹ÝÀÀ
°¨¿°
µå¹°°Ô: ´« °¨¿° (¾ÇÈ ¶Ç´Â 2Â÷°¨¿°)
½Å°æ°è
µå¹°°Ô: ½Ã¾ß°á¼Õ, ½Ã·ÂÀúÇÏ
¼ÒȰè
¾Ë ¼ö ¾øÀ½: ¹Ì°¢ÀÌ»ó
Àü½Å ¹× Åõ¿©ºÎÀ§ ÀÌ»ó
µå¹°°Ô: Ä¡À¯Àå¾Ö
2) ÷°¡Á¦ : ÀÌ ¾àÀº Àλ꿰À» Æ÷ÇÔÇϰí ÀÖ´Ù.
»ó´çÇÑ °¢¸· ¼Õ»óÀÌ ÀÖ´Â ÀϺΠȯÀÚ¿¡¼ Àλ꿰 ÇÔÀ¯ Á¡¾È¾×ÀÇ »ç¿ë°ú ¿¬°üµÇ¾î °¢¸· ¼®È¸ÈÀÇ »ç·Ê°¡ ¸Å¿ì µå¹°°Ô(0.01% ¹Ì¸¸) º¸°íµÈ ¹Ù ÀÖ´Ù.
»óÈ£ÀÛ¿ë
1) ¿Ü¿ë ¾È°ú¿ë ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵尡 °¢¸· â»ó Ä¡À¯¸¦ ´ÊÃâ ¼ö ÀÖ´Ù. ¿Ü¿ë NSAID ¿ª½Ã Ä¡À¯¸¦ ´ÊÃ߰ųª Áö¿¬½ÃŰ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¿Ü¿ë NSAID¿Í ¿Ü¿ë ½ºÅ×·ÎÀ̵åÀÇ µ¿½Ã »ç¿ëÀº Ä¡À¯ ¹®Á¦ÀÇ °¡´É¼ºÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
2) CYP3A4 ÀúÇØÁ¦ (¸®Å䳪ºñ¸£ ¶Ç´Â ÄÚºñ½Ã½ºÅ¸Æ® Æ÷ÇÔ)¿Í º´¿ë Åõ¿©½Ã Àü½Å ³ëÃâÀÌ Áõ°¡µÇ¾î, Àü½ÅÀû ÀÌ»ó ¹ÝÀÀ ¹ß»ý À§ÇèÀÌ Áõ°¡ÇÒ ¼ö ÀÖ´Ù. Ä¡·á»óÀÇ À¯ÀͼºÀÌ Àü½Å ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÀÌ»ó¹ÝÀÀ ¹ß»ýÀÇ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ º´¿ë Åõ¿©Çϸç, ȯÀÚÀÇ Àü½Å ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ¿µÇâÀ» »ìÆì¾ß ÇÑ´Ù.
Related FDA Approved Drug
±âÁØ ¼ººÐ:
FLUOROMETHOLONE ACETATE FLAREX (FLUOROMETHOLONE ACETATE)
TOBRASONE (FLUOROMETHOLONE ACETATE; TOBRAMYCIN)
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
(fluorometholone acetate opthalmic )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Á¦Çüº° º¹¾àÁöµµ
[Á¡¾È¾×]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Fluorometholone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Pharmacology
Fluorometholone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Corticosteroids such as fluorometholone inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.
Metabolism
Fluorometholone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
Protein Binding
Fluorometholone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
Half-life
Fluorometholone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
Absorption
Fluorometholone¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
Pharmacokinetics
Fluorometholone acetateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
Èí¼ö : ´ëºÎºÐÀº ¹æ¼ö(aqueous humor)·Î Èí¼öµÇ°í ¼Ò·®ÀÌ Àü½ÅÈí¼ö µÈ´Ù.
Biotransformation
Fluorometholone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Toxicity
Fluorometholone¿¡ ´ëÇÑ Toxicity Á¤º¸ Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD50 = 234 mg/kg (rats)
Drug Interactions
Fluorometholone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Drug Target
[Drug Target]
Description
Fluorometholone¿¡ ´ëÇÑ Description Á¤º¸ A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
Dosage Form
Fluorometholone¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Solution / drops OphthalmicSuspension Ophthalmic
Drug Category
Fluorometholone¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Allergic AgentsAnti-inflammatory AgentsGlucocorticoids
Smiles String Canonical
Fluorometholone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1CC2C3CCC(O)(C(C)=O)C3(C)CC(O)C2(F)C2(C)C=CC(=O)C=C12
Smiles String Isomeric
Fluorometholone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12
InChI Identifier
Fluorometholone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
Chemical IUPAC Name
Fluorometholone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ